$25.46
0.421.68%
Last update: Oct 26, 4:28 PM
Stoke Therapeutics Inc (STOK) Stock Price, Quote, News & History
STOKNASDAQ
Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million upfront and milestone payments.
You can purchase shares of Stoke Therapeutics (NASDAQ:STOK) through any online brokerage.
Other companies in Stoke Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Stoke Therapeutics has a consensus price target of $41.15.
The stock price for Stoke Therapeutics (NASDAQ: STOK) is $25.46 last updated October 26, 2026 at 4:28 PM EDT.
There are no upcoming dividends for Stoke Therapeutics.
Stoke Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Stoke Therapeutics.
Stoke Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing...
